

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

FEB 21 2006

Applicants : Asghar, et al.

Serial No. : 09/381,055

Filed : September 13, 1999

For : COMPOSITIONS COMPRISING COMPOUNDS WITH NMDA  
RECEPTOR ANTAGONIST ACTIVITY AND THEIR USE IN  
THE TREATMENT OF IRRITABLE BOWEL SYNDROME

Examiner : D. Lukton

Group Art Unit : 1653

<b>CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8</b>	
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below at the facsimile number <u>571-273-8300.</u>	
<u>Richard J. Sterner</u>	<u>35,372</u>
Agent Name	PTO Reg. No.
<u>Richard J. Sterner</u>	<u>February 21, 2006</u>
Signature	Date of Signature

Attention: Examiner D. Lukton  
Group Art Unit: 1653  
Facsimile No.: 571-273-8300  
No. of Pages: 6

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with 37 CFR §1.56 and in accordance with 37  
CFR §§1.97 and 1.98, it is requested that the single reference  
listed on the attached Form PTO/SB/08A be made of record in this  
application. A copy of the reference is enclosed.

02/23/2006 NGUYEN1 00000058 231703 09381055

01 FC:1806 180.00 DA


NEWYORK 5443269 v1 (5443560, 1 DOC) (2K)

This reference is being provided as support for Applicants' arguments presented in the Amendment and Response also being submitted on today's date.

This Information Disclosure Statement is being submitted under 37 CFR §1.97(c). The Commissioner is hereby authorized to charge the \$180 fee set forth in 37 CFR §1.17(p) to Deposit Account No. 23-1703. Any other fee(s) which may be due for any reason in connection with this communication may likewise be charged.

Dated: February 21, 2006

Respectfully submitted,

  
Richard J. Sterner  
Reg. No. 35,372

Customer No. 007470  
(212) 819-8200

Agent's Direct line:  
(212) 819-8783

Enclosures

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known**

Application Number	09/381,055
Filing Date	September 13, 1999
First Named Inventor	A. Asghar
Art Unit	1653
Examiner Name	D. Lukton
Attorney Docket Number	1103326-0590

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>5</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
		N. GAETANI, "IBS and IBD: Two Very Different Disorders," Crohn's & Colitis Foundation of America Website, 3 pages, posted Oct. 6, 2005	

Examiner Signature

Date Considered

<sup>1</sup>EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance but not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 1). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor may precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.95. The information is required to obtain or retain a benefit by the parties which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is optional to take 2 boxes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.